{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:39:48Z","timestamp":1793734788385,"version":"4.6.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Oncode Institute; Clinical Proof of Concept grant"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60281-8","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T17:13:35Z","timestamp":1748452415000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7478-2423","authenticated-orcid":false,"given":"Mitchell","family":"Emmers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9809-8266","authenticated-orcid":false,"given":"Marij J. P.","family":"Welters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle V.","family":"Dietz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia J.","family":"Santegoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanne","family":"Boekesteijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"Stolk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki M.","family":"Loof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie L.","family":"Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4975-9848","authenticated-orcid":false,"given":"Lauri C.","family":"Steinbusch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2020-9037","authenticated-orcid":false,"given":"A. Rob P. M.","family":"Valentijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6122-1024","authenticated-orcid":false,"given":"Noel F. C. C.","family":"de Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egbert F.","family":"Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9270-8636","authenticated-orcid":false,"given":"Hans","family":"Gelderblom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9115-558X","authenticated-orcid":false,"given":"Thorbald","family":"van Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6662-2951","authenticated-orcid":false,"given":"Joachim G.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6556-0354","authenticated-orcid":false,"given":"Sjoerd H.","family":"van der Burg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"60281_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","volume":"20","author":"A Kalbasi","year":"2020","unstructured":"Kalbasi, A. & Ribas, A. Tumour-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25\u201339 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"60281_CR2","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707\u2013723 (2017).","journal-title":"Cell"},{"key":"60281_CR3","doi-asserted-by":"publisher","first-page":"51","DOI":"10.3892\/mco.2013.194","volume":"2","author":"YX Ren","year":"2014","unstructured":"Ren, Y. X. et al. Downregulation of expression of transporters associated with antigen processing 1 and 2 and human leukocyte antigen I and its effect on immunity in nasopharyngeal carcinoma patients. Mol. Clin. Oncol. 2, 51\u201358 (2014).","journal-title":"Mol. Clin. Oncol."},{"key":"60281_CR4","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1016\/j.humpath.2010.05.014","volume":"41","author":"A Kasajima","year":"2010","unstructured":"Kasajima, A. et al. Down-regulation of the antigen processing machinery is linked to a loss of inflammatory response in colorectal cancer. Hum. Pathol. 41, 1758\u20131769 (2010).","journal-title":"Hum. Pathol."},{"key":"60281_CR5","doi-asserted-by":"publisher","first-page":"933","DOI":"10.3892\/or_00000717","volume":"23","author":"N Bandoh","year":"2010","unstructured":"Bandoh, N. et al. HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol. Rep. 23, 933\u2013939 (2010).","journal-title":"Oncol. Rep."},{"key":"60281_CR6","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00262-009-0769-5","volume":"59","author":"B Seliger","year":"2010","unstructured":"Seliger, B. et al. Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer. Cancer Immunol. Immunother. 59, 529\u2013540 (2010).","journal-title":"Cancer Immunol. Immunother."},{"key":"60281_CR7","first-page":"88","volume":"158","author":"J Tao","year":"2008","unstructured":"Tao, J. et al. Expression of transporters associated with antigen processing and human leucocyte antigen class I in malignant melanoma and its association with prognostic factors. Br. J. Dermatol 158, 88\u201394 (2008).","journal-title":"Br. J. Dermatol"},{"key":"60281_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-07603-1","volume":"9","author":"A Durgeau","year":"2018","unstructured":"Durgeau, A. et al. Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours. Nat. Commun. 9, 5097 (2018).","journal-title":"Nat. Commun."},{"key":"60281_CR9","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1093\/jnci\/djt184","volume":"105","author":"P Leone","year":"2013","unstructured":"Leone, P. et al. MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells. J. Natl. Cancer Inst. 105, 1172\u20131187 (2013).","journal-title":"J. Natl. Cancer Inst."},{"key":"60281_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-016-0990-x","volume":"14","author":"T Seremet","year":"2016","unstructured":"Seremet, T. et al. Molecular and epigenetic features of melanomas and tumor immune microenvironment linked to durable remission to ipilimumab-based immunotherapy in metastatic patients. J. Transl. Med. 14, 232 (2016).","journal-title":"J. Transl. Med."},{"key":"60281_CR11","doi-asserted-by":"publisher","first-page":"e1382793","DOI":"10.1080\/2162402X.2017.1382793","volume":"7","author":"EM Doorduijn","year":"2018","unstructured":"Doorduijn, E. M. et al. T cells specific for a TAP-independent self-peptide remain naive in tumor-bearing mice and are fully exploitable for therapy. Oncoimmunology 7, e1382793 (2018).","journal-title":"Oncoimmunology"},{"key":"60281_CR12","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1172\/JCI83671","volume":"126","author":"EM Doorduijn","year":"2016","unstructured":"Doorduijn, E. M. et al. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors. J. Clin. Investig. 126, 784\u2013794 (2016).","journal-title":"J. Clin. Investig."},{"key":"60281_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nm1381","volume":"12","author":"T van Hall","year":"2006","unstructured":"van Hall, T. et al. Selective cytotoxic T-lymphocyte targeting of tumor immune escape variants. Nat. Med. 12, 417\u2013424 (2006).","journal-title":"Nat. Med."},{"key":"60281_CR14","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1084\/jem.20180577","volume":"215","author":"KA Marijt","year":"2018","unstructured":"Marijt, K. A. et al. Identification of non-mutated neoantigens presented by TAP-deficient tumors. J. Exp. Med. 215, 2325\u20132337 (2018).","journal-title":"J. Exp. Med."},{"key":"60281_CR15","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa0810097","volume":"361","author":"GG Kenter","year":"2009","unstructured":"Kenter, G. G. et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N. Engl. J. Med. 361, 1838\u20131847 (2009).","journal-title":"N. Engl. J. Med."},{"key":"60281_CR16","doi-asserted-by":"publisher","first-page":"eaaz8235","DOI":"10.1126\/scitranslmed.aaz8235","volume":"12","author":"CJM Melief","year":"2020","unstructured":"Melief, C. J. M. et al. Strong vaccine responses during chemotherapy are associated with prolonged cancer survival. Sci. Transl. Med. 12, eaaz8235 (2020).","journal-title":"Sci. Transl. Med."},{"key":"60281_CR17","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1007\/s00262-021-02984-7","volume":"71","author":"KA Marijt","year":"2022","unstructured":"Marijt, K. A., Griffioen, L., Blijleven, L., van der Burg, S. H. & van Hall, T. Cross-presentation of a TAP-independent signal peptide induces CD8 T immunity to escaped cancers but necessitates anchor replacement. Cancer Immunol. Immunother. 71, 289\u2013300 (2022).","journal-title":"Cancer Immunol. Immunother."},{"key":"60281_CR18","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1200\/JCO.19.00934","volume":"37","author":"EB Garon","year":"2019","unstructured":"Garon, E. B. et al. Five-year overall survival for patients with advanced nonsmall-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. J. Clin. Oncol. 37, 2518\u20132527 (2019).","journal-title":"J. Clin. Oncol."},{"key":"60281_CR19","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/bjc.1996.28","volume":"73","author":"P Korkolopoulou","year":"1996","unstructured":"Korkolopoulou, P., Kaklamanis, L., Pezzella, F., Harris, A. L. & Gatter, K. C. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br. J. Cancer 73, 148\u2013153 (1996).","journal-title":"Br. J. Cancer"},{"key":"60281_CR20","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1038\/s41586-018-0810-y","volume":"565","author":"N Hilf","year":"2019","unstructured":"Hilf, N. et al. Actively personalized vaccination trial for newly diagnosed glioblastoma. Nature 565, 240\u2013245 (2019).","journal-title":"Nature"},{"key":"60281_CR21","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/s41586-018-0792-9","volume":"565","author":"DB Keskin","year":"2019","unstructured":"Keskin, D. B. et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature 565, 234\u2013239 (2019).","journal-title":"Nature"},{"key":"60281_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature22991","volume":"547","author":"PA Ott","year":"2017","unstructured":"Ott, P. A. et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature 547, 217\u2013221 (2017).","journal-title":"Nature"},{"key":"60281_CR23","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cell.2020.08.053","volume":"183","author":"PA Ott","year":"2020","unstructured":"Ott, P. A. et al. A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer. Cell 183, 347\u2013362.e324 (2020).","journal-title":"Cell"},{"key":"60281_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/s41586-020-2537-9","volume":"585","author":"U Sahin","year":"2020","unstructured":"Sahin, U. et al. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature 585, 107\u2013112 (2020).","journal-title":"Nature"},{"key":"60281_CR25","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.annonc.2023.07.006","volume":"34","author":"B Besse","year":"2023","unstructured":"Besse, B. et al. Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1. Ann. Oncol. 34, 920\u2013933 (2023).","journal-title":"Ann. Oncol."},{"key":"60281_CR26","doi-asserted-by":"publisher","first-page":"e007697","DOI":"10.1136\/jitc-2023-007697","volume":"11","author":"EME Verdegaal","year":"2023","unstructured":"Verdegaal, E. M. E. et al. Timed adoptive T cell transfer during chemotherapy in patients with recurrent platinum-sensitive epithelial ovarian cancer. J. Immunother. Cancer 11, e007697 (2023).","journal-title":"J. Immunother. Cancer"},{"key":"60281_CR27","doi-asserted-by":"publisher","first-page":"334ra352","DOI":"10.1126\/scitranslmed.aad8307","volume":"8","author":"MJ Welters","year":"2016","unstructured":"Welters, M. J. et al. Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses. Sci. Transl. Med. 8, 334ra352 (2016).","journal-title":"Sci. Transl. Med."},{"key":"60281_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31721-6","volume":"13","author":"IN Pardieck","year":"2022","unstructured":"Pardieck, I. N. et al. A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infection. Nat. Commun. 13, 3966 (2022).","journal-title":"Nat. Commun."},{"key":"60281_CR29","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41586-023-06063-y","volume":"618","author":"LA Rojas","year":"2023","unstructured":"Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144\u2013150 (2023).","journal-title":"Nature"},{"key":"60281_CR30","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/nature23003","volume":"547","author":"U Sahin","year":"2017","unstructured":"Sahin, U. et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature 547, 222\u2013226 (2017).","journal-title":"Nature"},{"key":"60281_CR31","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.molimm.2018.03.029","volume":"113","author":"KA Marijt","year":"2019","unstructured":"Marijt, K. A., Doorduijn, E. M. & van Hall, T. TEIPP antigens for T-cell based immunotherapy of immune-edited HLA class I(low) cancers. Mol. Immunol. 113, 43\u201349 (2019).","journal-title":"Mol. Immunol."},{"key":"60281_CR32","doi-asserted-by":"publisher","first-page":"4029","DOI":"10.1016\/j.radcr.2024.06.046","volume":"19","author":"SJ Lee","year":"2024","unstructured":"Lee, S. J. et al. Pseudoprogression following neoadjuvant chemoimmunotherapy for lung squamous cell carcinoma mimicking pulmonary metastatic disease on computed tomography: A case report and review of the literature. Radio. Case Rep. 19, 4029\u20134033 (2024).","journal-title":"Radio. Case Rep."},{"key":"60281_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nature19330","volume":"537","author":"SJ Im","year":"2016","unstructured":"Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417\u2013421 (2016).","journal-title":"Nature"},{"key":"60281_CR34","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.immuni.2018.12.021","volume":"50","author":"I Siddiqui","year":"2019","unstructured":"Siddiqui, I. et al. Intratumoral Tcf1(+)PD-1(+)CD8(+) T Cells with Stem-like Properties Promote Tumor Control in Response to Vaccination and Checkpoint Blockade Immunotherapy. Immunity 50, 195\u2013211.e110 (2019).","journal-title":"Immunity"},{"key":"60281_CR35","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ccell.2020.09.001","volume":"38","author":"F Dammeijer","year":"2020","unstructured":"Dammeijer, F. et al. The PD-1\/PD-L1-checkpoint restrains T cell immunity in tumor-draining lymph nodes. Cancer Cell 38, 685\u2013700 e688 (2020).","journal-title":"Cancer Cell"},{"key":"60281_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","volume":"25","author":"AC Huang","year":"2019","unstructured":"Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454\u2013461 (2019).","journal-title":"Nat. Med."},{"key":"60281_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh, S. A. et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat. Cancer 1, 681\u2013691 (2020).","journal-title":"Nat. Cancer"},{"key":"60281_CR38","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41586-020-2056-8","volume":"579","author":"TD Wu","year":"2020","unstructured":"Wu, T. D. et al. Peripheral T cell expansion predicts tumour infiltration and clinical response. Nature 579, 274\u2013278 (2020).","journal-title":"Nature"},{"key":"60281_CR39","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1158\/1078-0432.CCR-15-2594","volume":"22","author":"MI van Poelgeest","year":"2016","unstructured":"van Poelgeest, M. I. et al. Vaccination against oncoproteins of HPV16 for noninvasive vulvar\/vaginal lesions: lesion clearance is related to the strength of the T-cell response. Clin. Cancer Res. 22, 2342\u20132350 (2016).","journal-title":"Clin. Cancer Res."},{"key":"60281_CR40","doi-asserted-by":"crossref","unstructured":"Hu, Z. et al. Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. Nat. Med. 27, 515\u2013525 (2021).","DOI":"10.1038\/s41591-020-01206-4"},{"key":"60281_CR41","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41568-021-00346-0","volume":"21","author":"M Saxena","year":"2021","unstructured":"Saxena, M., van der Burg, S. H., Melief, C. J. M. & Bhardwaj, N. Therapeutic cancer vaccines. Nat. Rev. Cancer 21, 360\u2013378 (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"60281_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.cji.0000211341.88835.ae","volume":"30","author":"A Hoos","year":"2007","unstructured":"Hoos, A. et al. A clinical development paradigm for cancer vaccines and related biologics. J. Immunother. 30, 1\u201315 (2007).","journal-title":"J. Immunother."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60281-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60281-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T18:02:04Z","timestamp":1748455324000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60281-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60281"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60281-8","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,28]]},"assertion":[{"value":"10 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H. and S.H.B. have filed a patent on the TEIPP24 vaccine. None of the other authors have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research aligns with the Inclusion & ethical guidelines embraced by Nature Communications.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"4958"}}